Armistice Capital LLC recently announced the acquisition of new stake in Altamira Therapeutics Ltd (NASDAQ:CYTO). This fresh investment now brings its stake to 9.39% valued currently at $0.12 million. In addition, G1 Execution Services LLC raised its holdings by 10185.0 to 10185.0 shares.
With over 12.01 million Altamira Therapeutics Ltd (CYTO) shares trading Friday and a closing price of $0.32 on the day, the dollar volume was approximately $3.84 million. The shares have shown a negative half year performance of -63.38% and its price on 12/01/23 lost nearly -18.46%. Currently, there are 8.83M common shares owned by the public and among those 8.78M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The analysts have set the share’s price value over the next 12 months at a high of $286.10 and a low of $286.10. The average price target is 99.89% above its recent price level and an upside to the estimated low will see the stock gain 99.89% over that period. But an upside of 99.89% will see the stock hit the forecast high price target while median target price for the stock is $286.10.
Shares of Altamira Therapeutics Ltd (NASDAQ: CYTO) opened at $0.4236, up $0.03 from a prior closing price of $0.39. However, the script later moved the day high at 0.4590, down -18.46%. The company’s stock has a 5-day price change of 12.72% and -10.89% over the past three months. CYTO shares are trading -93.42% year to date (YTD), with the 12-month market performance down to -94.35% lower. It has a 12-month low price of $0.09 and touched a high of $6.00 over the same period. CYTO has an average intraday trading volume of 12.44 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 46.76%, 51.68%, and -57.57% respectively.
Institutional ownership of Altamira Therapeutics Ltd (NASDAQ: CYTO) shares accounts for 10.07% of the company’s 8.83M shares outstanding. Mutual fund holders own 0.01%, while other institutional holders and individual stakeholders account for 10.06% and — respectively.
It has a market capitalization of $2.82M and a beta (3y monthly) value of 2.48. Price movements for the stock have been influenced by the stock’s volatility, which stands at 101.41% over the week and 48.76% over the month.
Analysts forecast that Altamira Therapeutics Ltd (CYTO) will achieve an EPS of $0 for the current quarter, $0 for the next quarter and $0 for 2022. The lowest estimate earnings-per-share for the quarter is $0 while analysts give the company a high EPS estimate of $0.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 1 brokerage firm advisors rate Altamira Therapeutics Ltd (CYTO) as a “Strong Buy” at a consensus score of 1.00. Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 0 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”
